Synthetic Drug 25I: A New Schedule I Drug

New Orleans Drug Crime Attorney


By Elizabeth B Carpenter — Criminal Defense Attorney New Orleans 


Elizabeth B Carpenter Law is a premier law firm for Drug Crime defense.  We have defended almost every type of Drug Crime imaginable in South Louisiana.   If you are in need of a New Orleans drug crime attorney, contact our office today.




Synthetic Drug 25I: A New Schedule I Drug

State health officials, top lawmakers and law enforcement personnel announce steps they have taken to ban a dangerous new drug, 25i, making it illegal in Louisiana.

This relatively new drug, 25i, also called Smiles or N-Bomb, has been added to the state’s Controlled Dangerous Substance Act, effective immediately.  It is classified as a Controlled Dangerous Substance — Schedule I.

Simple Possession of 25I will carry a sentence of 4 to 10 years.

Manufacturing and Distribution of 25I will carry a sentence of 5 to 50 years.

Lawmakers began eyeing criminalizing the drug after an Arkansas man died last week in New Orleans after reportedly overdosing on 25i at a festival.

At least five people have died nationwide this year after taking 25i, including the man who died in Louisiana, according to officials. Other deaths reportedly occurred in Minnesota, North Dakota, California and North Carolina.  Today, Louisiana becomes the second state, along with Virginia, to make 25i illegal.

Louisiana revised statute 40:962, gives State Health Officials authority to add new compounds as a Schedule I drug in the Controlled Dangerous Substance Act by rule if the substance has a high potential for abuse, has no currently accepted medical use in the U.S., and if there is no accepted safety use of the substance under medical supervision.

Officials said the synthetic drug is commonly manufactured in China and India, and is being sold in powder and liquid form online, which is how people access it in the United States.


Elizabeth B Carpenter — New Orleans Criminal Defense Attorney


Please follow and like us:
This website uses cookies and third party services. Ok